To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

Also called NCT06647550

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 160 participants (planned count) (from the registry)
Sponsor
  • Hyundai Pharm Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06647550
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06647550. Randomized; double masking; primary purpose treatment. Start 2024-12-12 (actual); primary completion 2025-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Assess the Efficacy and Safety of HD-6277 in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus by Diet and Exercise
Acronym
HDNO-1605
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
HD-6277 100mg
Intervention (Drug)
HD-6277 50mg
Intervention (Drug)
HD-6277 25mg
Intervention (Drug)
Placebo
Lead sponsor
Hyundai Pharm (class: industry)

Record details

Record id
cardio:ct-nct06647550
Content hash
95c8c0df2828875f7ded32c24b5fe0df2fc871c4333b273cc48b483e3dc9840c